ACHE and Alzheimer disease: The current clinical therapy for AD is mainly divided in acetylcholinesterase inhibitors (AChEIs), represented by Donepezil, Galantamine, Rivastigmine, and Tacrine, which has already been discontinued due to its hepatoxicity, and the antagonist of the N-methyl-D-aspartic acid (NMDA) receptor, Memantine, all approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) [1,5].